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There is controversy whether children should have a dietary supply of preformed long-chain polyunsaturated n-3 fatty acids EPA and DHA. The
aims of the workshop were to review evidence for a possible benefit of a preformed EPA and/or DHA supply, of data required to set desirable
intakes for children aged 2–12 years, and of research priorities. The authors concluded that EPA and DHA intakes per kg body weight may often
be low in 2- to 12-year-old children, relative to intakes per kg body weight of breast-fed infants and adult intakes, but reliable data are scarce. Little
information is available that increasing dietary intakes of EPA or DHA in children has benefits to physical or mental function or other health
endpoints. Studies addressing EPA and DHA intakes and tissue status among groups of children with different dietary habits, and measures of
relevant development and health endpoints, are needed for developing potential advice on desirable intakes of EPA and/or DHA in children.
At this time it appears prudent to advise that dietary intakes in childhood are consistent with future eating patterns supporting adult health,
such as prevention of metabolic disorders and CVD, supporting immune function, and reproductive health. In conclusion, the available information
relating dietary EPA and DHA intakes in children aged 2–12 years to growth, development and health is insufficient to derive dietary intake
recommendations for EPA and DHA. Adequately designed studies addressing dietary intakes, measures of status and relevant functional or
health effects across this age group are needed.
EPA: DHA: n-3 Long-chain PUFA: Reference nutrient values: RDA
Several national and international organisations have provided
guidance on desirable dietary intakes of the long-chain PUFA
DHA and EPA from fish for adults and for infants (Table 1).
For adults, these recommendations are based mainly on
primary and secondary prevention of CVD, ranging from
one to two portions of fatty fish per week or about 500 mg
EPA and DHA per d(1,2). For pregnant and lactating women,
the advice of an average daily intake of at least 200 mg
DHA is based on optimal pregnancy outcomes(3 – 5), and on
possible beneficial effects on fetal and infant development(6,7).
For infants (0–2 years of age), in 1994, the FAO/WHO(8)
recommended 20 mg DHA per kg body weight per d for
optimal growth and development. However, there are no
agreed recommendations for the advisable dietary intake of
EPA and/or DHA for children above 2 years of age.
A workshop was organised in July 2007 to review and
discuss the available evidence on dietary intakes of EPA
and DHA and their potential physiological relevance to
growth and health in children, and to evaluate whether there
are sufficient scientific data for issuing evidence-based guide-
lines on EPA and DHA intake in 2- to 12-year-old children.
The present paper summarises the outcomes of the discussions
held at the workshop on current knowledge of dietary intakes
among children 2–12 years of age and published literature
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regarding the potential importance of EPA and DHA at this
stage of the life cycle.
EPA and DHA intakes in children
The richest food sources of both EPA and DHA are fatty fish,
with smaller amounts in lean fish and other seafood(9,10). The
distributions of dietary EPA and DHA intakes within popu-
lations are generally skewed with lower median than mean
intakes, explained by a substantial number of individuals
eating no or very little fish(10 – 12). However, information of
dietary intakes of EPA and DHA, particularly among children,
is limited. This has several reasons, including the limitations
of dietary intake methodology, collecting accurate information
on dietary intakes from children, and the completeness of
fatty acid data on foods listed in databases. For example, the
fat and fatty acid composition of fish varies widely, meaning
that specific information on the types of fish and seafood
consumed is essential; eggs can be an important source of
fatty acids and are often hidden in other foods such as cakes
and puddings, but depending on the recall method their
intake may be missed. Moreover, children frequently consume
food outside of the home, and without the parents’ knowledge.
The rather limited available information on dietary intake in
children suggests that EPA and DHA intake tends to be lower
than in adults(13). Similarly, the intake of children may also be
lower per kg body weight than in infants who are breast-fed or
fed infant formulas containing DHA(7,14). Children’s current
dietary intake of EPA and DHA may also be lower than
some decades ago(15). Whether current intakes of EPA and
DHA among children are adequate for optimal functional
and health outcomes requires information on dietary intakes
of children following different diets together with measures
of functional endpoints sensitive to potential biological
effects of these fatty acids. It is conceivable that EPA and/
or DHA intakes might contribute to health promotion and
chronic disease prevention, but reliable and comparable data
on dietary intake of n-3 fatty acids and on biochemical mar-
kers of status in different populations of children are scarce.
The available data do not allow us to conclude that changing
intakes of EPA and/or DHA can affect physical or mental
development or yield specific functional benefits.
The effects of EPA and DHA on biological function, health
and prevention of disease
Historically, recommended intake levels for nutrients have
been defined to prevent signs of deficiency in the general
population. In recent years, however, nutritional recommen-
dations and guidelines are being progressively formulated
based on evidence linking specific nutrients at given intakes
to disease prevention and optimal performance and
health(16). An example is the Acceptable Macronutrient Distri-
bution Range used by the Institute of Medicine(17), which
represents the range of energy intakes from the different
macronutrient intakes that, when consumed as part of a diet
providing an appropriate amount of energy to maintain ideal
body weight, are associated with low risk of chronic disease.
Individuals that have low EPA and/or DHA intakes but
eat plentiful sources of a-linolenic acid, such as vegans and
vegetarians, do have a lower EPA and DHA status than omni-
vores, but are not known to develop signs of deficiency(18).
Table 1. Recommendations for daily intake of DHA and EPA in adults and infants
Institution Adults Infants
FAO/WHO (1994)(8) – 20 mg DHA/kg BW
Agence Franc¸aise de Se´curite´ Sanitaire
des Aliments & CNERNA-CNRS(49)
DHA: 0·05 % energy –
Men: 120 mg DHA
Women: 100 mg DHA
Health Council of The Netherlands(50) 200 mg EPA þ DHA 20 mg DHA/kg BW
European Commission Directorate General
for Health and Consumer Protection (Unit F/3)(51)
200 mg EPA þ DHA –
WHO (2003)(52) 400–1000 mg EPA þ DHA as one
or two portions fish per week
–
UK Scientific Advisory Committee on Nutrition(53) Assumes 450 mg EPA þ DHA as
two portions fish per week
–
International Society for the Study of Fatty
Acids and Lipids (2004)(54)
.500 mg EPA þ DHA –
Conseil Supe´rieur d’Hygie`ne, Service Public
Fe´de´ral de la Sante´ Publique, Belgium(55)
.0·3 % energy EPA: 0·05–0·15 % energy
670 mg EPA þ DHA DHA: 0·10–0·40 % energy
Deutsche Gesellschaft fu¨r Erna¨hrung (2005)(56) 250 mg EPA þ DHA –
Consensus recommendation*(6) $200 mg DHA during pregnancy and lactation –
Position of the American Dietetic Association
and Dietitians of Canada(2)
500 mg EPA þ DHA –
World Association of Perinatal Medicine, Early
Nutrition Academy and Child Health Foundation(7)
$200 mg DHA during pregnancy and lactation Infant formulae and baby foods:
DHA: 0·2–0·5 % of fatty acids
EPA # DHA, AA $ DHA
BW, body weight; CNERNA-CNRS, Centre Nationale d’Etudes et de Recommendations sur la Nutrition et l’Alimentation & Centre National de la Recherche Scientifique;
AA, arachidonic acid.
* Supported by Perinatal Lipid Nutrition Project, Early Nutrition Programming Project, Child Health Foundation, Diabetic Pregnancy Study Group, European Association of Peri-
natal Medicine, European Society for Clinical Nutrition and Metabolism, European Society for Paediatric Gastroenterology, Hepatology and Nutrition, International Federation
of Placenta Associations, and International Society for the Study of Fatty Acids and Lipids.
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Higher intake levels of EPA and DHA have been associated
with a range of possible physiological and health benefits in
humans(19), such as the improvement in neurological functions
in infancy(20), the primary and secondary prevention of CVD
and the metabolic syndrome in adults(1,21), modulation of
immune response(22) and improved pregnancy outcomes(3 – 5).
The evidence for beneficial effects of EPA and DHA intakes
on health outcomes in children is limited and will be summar-
ised here.
The importance of attaining optimal brain and retina DHA
for visual and neurological development and function is
considered critical in the perinatal period(23). Beyond infancy,
evidence linking DHA intake or blood levels of DHA with
neurological benefits is limited to children following restricted
diets with very low dietary intakes of EPA and DHA, such as
children with phenylketonuria(24 – 26). These studies show that
increasing DHA status with fish oil supplements is consistent
with improvements in speed of information processing in the
central nervous system as assessed by latencies of visual
evoked potentials(24), as well as significant improvements of
coordination and fine motor skills(25). These findings indicate
that a continuous dietary supply of preformed DHA and/or
EPA may be essential for achieving optimal neural function
even in children who have a high intake of the precursor
a-linolenic acid with restricted diets due to phenylketo-
nuria(27). This conclusion may be relevant for healthy children
as well, since children with early treated phenylketonuria are
generally healthy and have no detectable alterations of
energy and fatty acid metabolism.
EPA and DHA in combination with n-6 fatty acids have
also been reported to improve behaviour in children with
neurodevelopmental disorders such as attention-deficit hyper-
activity disorder and dyspraxia in some(28 – 30) but not
all(31,32) studies. A recent systematic review of these studies
concluded that there is insufficient evidence to identify any
effect of nutrition, diet and dietary change on learning,
education or performance of school-aged children from the
developed world(33). Further research of high quality, repre-
sentative of all populations, undertaken for longer durations
and using universal standardised measures of educational
attainment is needed(33) and should evaluate the potential
relative roles of EPA and DHA, respectively, in children
with neurodevelopmental disorders.
High intakes of EPA and/or DHA may beneficially modu-
late the immune system by decreasing the synthesis of
pro-inflammatory arachidonic acid-derived eicosanoids(34)
and by shifting the balance of T helper 1 (Th1), T helper 2
(Th2) and T regulatory cells(35). Evidence for beneficial
effects on asthma in children is not established, but some
studies suggested that for certain subgroups of respondent
children, symptoms of asthma may be alleviated with DHA/
EPA supplementation(36). It is unclear to what extent these
and other observations using high dosages of EPA and DHA
supplements relate to possible effects with lower intakes
achieved with foods.
A regular intake of fatty fish is widely advised to adult
populations for the prevention of CVD, and a large part of
associated beneficial effects is thought to be mediated by the
supply of EPA and DHA with fatty fish(1). Potential beneficial
effects of EPA and DHA intakes in children on their future
risk of developing CVD have not been documented. However,
food preferences and eating habits that are established in
childhood appear to show a certain degree of tracking into
adulthood(37,38). Therefore, it seems desirable to accustom
children to dietary patterns that are likely to promote health
in adulthood.
Approaches to develop possible advice on dietary intakes
of EPA and DHA
Advice on dietary nutrient intake values for children is based
on a variety of different methodological approaches, including
consideration of deficiency states, usual intake levels, factorial
approaches to calculate needs for maintenance and growth,
effects on physiological function and health(39) and extrapol-
ation from reference values established for other age groups
such as adults or infants(40). The authors of the present
paper conclude that the current lack of reliable data on the
relationship between EPA and DHA intake or status and func-
tional and health outcomes in 2- to 12-year-old children does
not allow determination of physiological requirements or
nutrient intake levels using classical approaches to derive
dietary recommendations. Extrapolating n-3 fatty acid intake
levels, including those for EPA and DHA, for children from
existing reference values for either adults or infants (Table 1)
seems inappropriate, not only because there is still consider-
able uncertainty regarding nutrient intake levels for DHA
and/or EPA in both adults and infants, but also because extra-
polation based for example on body mass or energy expendi-
ture is expected to inadequately reflect age-specific
physiological requirements, such as continuing neurological
development and lean tissue growth, that determine dietary
nutrient needs(40). Thus, at present the available evidence is
insufficient to formulate quantitative nutrient intake values
for EPA and DHA in children. However, it seems reasonable
that dietary advice for children should be consistent with
advice for the adult population, such as regular intake of
one to two fatty fish meals per week providing DHA and
EPA associated with the risk reduction of CVD. If such a
habit can be established early in life and be maintained, it
may also support a desirable long-chain n-3 fatty acid
supply among females of child-bearing age to support optimal
pregnancy outcomes. There is no reason why children in a
family setting should be excluded from the consumption of
at least one to two meals of fatty fish per week, which is
recommended for the adult population(2).
Present and future research
The possible relationships between intake and effects of DHA
and/or EPA need to be studied in detail. Presently, the
research project ‘Nutrition and Mental Health’ funded by the
European Commission’s 7th Framework Research Programme
will try to establish whether there is a relationship between the
level of dietary DHA supply and neurological functions
in children. Further studies should also include evaluating
effects of the intake of a-linolenic acid, as well as factors
affecting its endogenous conversion to EPA and DHA, such
as the concomitant intake of linoleic acid(41) and the role of
genetic polymorphisms of the desaturating enzymes D-6 and
D-5 desaturases(42).
EPA and DHA intake in children 925
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Relevant public health outcomes that are likely to be linked
to lifelong intakes of EPA and DHA include the risk of
(future) CVD and the metabolic syndrome, optimal mental
development and behaviour, and immune response.
Dietary studies should be carefully conducted and analysed,
with a specific and standardised methodology, considering
the substantial challenges in assessing individual intakes of
EPA and DHA in children. Since assessment methods for
dietary intake are imprecise, age-specific information on
fatty acid status based on biological markers are also required.
Cross-sectional analyses from prospective birth and
childhood cohort studies are likely to provide valuable
insights that can contribute to designing intervention trials.
Age-specific effects of different fatty acid intakes and dosages
on relevant endpoints should be assessed in controlled
intervention studies. The data obtained should aim at estab-
lishing the effect of different doses of individual fatty acids,
and of different combinations and ratios of PUFA, on
well-defined and quantifiable outcomes. Such outcomes may
include:
(1) Markers of cardiovascular risk and the metabolic syn-
drome;
(2) Measures of neural function, cognition and behaviour;
(3) Markers of inflammatory response, immune function and
their related diseases, such as allergy or autoimmune
disease.
Studies in children aiming at evaluating these and other
outcomes must respect the limitations determined by the
ethical rules for research with children(43,44).
Although recent risk analyses tend to support the safety
and overall benefit of increased fish consumption(45,46),
potential adverse effects of recommending increased dietary
intakes of EPA and DHA from fish oil concentrates or fatty
fish, such as the risk of adverse effects of contamination
with environmental pollutants(47,48), should be taken into
account.
Conclusions
A better understanding of the functional roles of EPA and
DHA in children is required in order to determine adequate
dietary intakes. Currently there is a lack of sufficient evidence
to link levels of dietary intake of DHA and/or EPA to
improved physical, mental or other functional benefits in chil-
dren. Therefore, quantitative dietary intake recommendations
for children cannot be established at this time.
Food-based dietary guidelines that apply to adults for
enhancing health and preventing chronic diseases such as
CVD will usually apply to the whole population, including
children, unless there are specific arguments for alternative
guidelines or recommendations. There is no reason why
children should be excluded from the advice to consume at
least one to two meals of fatty fish per week as recommended
for adults. Establishing a quantitative dietary intake
recommendation for EPA and DHA for children aged 2–12
years will require a research programme focusing on well-
defined, public health-relevant and age-specific outcomes in
this specific age group.
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